The present study further demonstrated the effectiveness of adjuvant goserelin 10.8-mg depot after an RP in suppressing serum testosterone and PSA levels in patients with localized or locally advanced prostate cancer (Figures S1 and S2). This evidence concerns the gene KLK3 and prostate cancer.